|
ADA
Jun 26, 2018 14:06:37 GMT -5
Post by mnkdfann on Jun 26, 2018 14:06:37 GMT -5
The price target did move as I recall didn't Wainwirght lower the target to $2 very recently? I think that $2 target was indeed a typo. Note in today's report, it is once again, " reiterate". All the recent reports from Wainwright has been "reiterate". It does not look like there was a downgrade recently. If there was a downgrade recently, then in today's report, it would be noted that it is an upgrade. Not sure what you consider 'recent', but there was a target price downgrade in May from $7 to $5. At the time, Wainwright reiterated its buy recommendation. Analysts give buy/hold/sell recommendations, and also price targets. They can change one or both at any time. One may change, one may stay the same. They might even change in different directions! E.g., From buy to sell, but the price target is raised. (I leave that as an exercise for the reader to work out.)
|
|
|
ADA
Jun 26, 2018 14:10:46 GMT -5
Post by mnkdfann on Jun 26, 2018 14:10:46 GMT -5
|
|
|
Post by joeypotsandpans on Jun 26, 2018 14:13:47 GMT -5
The price target did move as I recall didn't Wainwirght lower the target to $2 very recently? I think that $2 target was indeed a typo. Note in today's report, it is once again, " reiterate". All the recent reports from Wainwright has been "reiterate". It does not look like there was a downgrade recently. If there was a downgrade recently, then in today's report, it would be noted that it is an upgrade. Analyst upgrades/downgrades are worth the same as or maybe even less than a SA writer's article in my opinion. The only upgrade that has any merit is an upgrade in scripts to people who desperately need to have better compliance/control of their BG. When that upgrade comes out, that is where you will see a huge tipping point, it will happen and with recent events hopefully that much closer to happening. After a high carb dinner yesterday and dosing with Afrezza 1hr after dinner and 1hr. after that, no basal, never would have happened previously, especially after bruschetta, caesar salad, lasagna, and black cherry ice cream with coffee. Sorry if that offends the cave man diet folks but every now and then I like to enjoy life the way I like to enjoy it.
|
|
|
Post by mnholdem on Jun 26, 2018 14:26:52 GMT -5
Was being sacastic... as we are currently at $2. You could take lessons from baba...he makes sarcasm seem effortless.
|
|
|
Post by mnkdfann on Jun 26, 2018 14:30:42 GMT -5
Re CMO's in general - this is from another company I'm in (loser), and this was meant to level criticism at the company in terms of being able to attract the right CMO (it was written by a sharp guy, so obviously, not me): "No self respecting CMO would join _____. Quality CMOs are in big demand, especially if they have taken a drug all the way through to approval. What would a CMO think when he arrived at the US location two floors above a massage parlor? Top CMOs are rock stars. Their image is very important to their position in the industry. What would a candidate CMO think upon learning the future of _____ was based upon retrospective (slice and dice) statistical findings? I think for the time being ____ is better off without a CMO." So happy we have our rockstar!! Baba only invests in companies with CEOs named Matt. Coffey, cough, cough.
|
|
|
ADA
Jun 26, 2018 17:45:42 GMT -5
Post by od on Jun 26, 2018 17:45:42 GMT -5
Brother - its been a long road and I am glad what I have been saying for years is now being understood and was demonstrated in an "Official, Peer Reviewed Study". One thing for sure, I am damn glad Dr. Kendall is there, could interrupt the results and present them in plain English and then put out the press release they did.
As far as Aged, we love Aged. While soft bashing afrezza for years, he/she has always been respectful and I for one always like a good challenge. Who is obsoleted are Aged's endos who 3+ years ago said afrezza would make your lungs explode and they are still teaching people the medically incorrect way to adjust their baseline.
Maybe now Aged will give afrezza a go, at least for the corrections. What I would now like to see is an "Official" study showing afrezza's use for corrections. How great would those results be?
I would leave aged alone. Aged is smart enough and knowledgeable enough to make his own decisions. if aged wanted afrezza he would have gotten it already. Aged knows how to stack and when to eat. Me, I am thankful, I do not have the malady. As far as type two, my plan would be to get the fat out of my cells, so insulin could once again have glucose enter my cells. The plan, diet, NO MEAT, NO Diary, NO oil. In this country so far we all get to make our own medical decisions, until we can't. Me, as long as I have consciousness, I do not intend to give my medical decisions to a human being that barely knows me and has 15 mins to determine what pill they can prescribe for their overlords benefit. one more thing, a physician can write a prescription, I do not have to fill it or take it. we get to choose. And aged comes in handy. "Put another log on the fire Cook me up some bacon and some beans And go out to the car and change the tire Wash my socks and sew my old blue jeans" www.youtube.com/watch?v=BWpYQjuJ0u0"I would leave aged alone. Aged is smart enough and knowledgeable enough to make his own decisions. if aged wanted afrezza he would have gotten it already. Aged knows how to stack and when to eat. Me, I am thankful, I do not have the malady."
Peppy, your comment brings me joy -- humanity lives, thank you.
|
|
|
Post by sportsrancho on Jun 26, 2018 17:58:37 GMT -5
|
|
|
Post by sayhey24 on Jun 26, 2018 18:33:31 GMT -5
ADA2018 exceeded my expectations with MNKD's STAT Study results. More important we have a defined action plan forward. Dr. Kendall needs to have the standard of care, the "PHARMACOLOGIC THERAPY FOR TYPE 1 DIABETES" rewritten to not only include afrezza but say afrezza should be frontline treatment for meal and pump bolasing. He can start with bullet 2 and should be able to do this in 6 months. care.diabetesjournals.org/content/41/Supplement_1/S73 After that he needs to have the PHARMACOLOGIC THERAPY FOR TYPE 2 DIABETES to include afrezza. This should be doable in 6 months. The third thing is he needs to have the "Recommendations" bullet three say afrezza should be used immediately for all PWDs over A1c 8.0 and all PWDs who do not reach 6.5 on Metformin in 6 months. Most of the rest of the bullets can be deleted as afrezza obsoletes their need. He should be able to this in 18 months but will need to bring the justification to ADA2019 as this is a huge battle, a $20B battle. If he can do these three things he will totally disrupt the diabetes industry and make MNKD a multi-$Billion company.
|
|
|
Post by agedhippie on Jun 27, 2018 9:59:17 GMT -5
Dr. Kendall needs to have the standard of care, the "PHARMACOLOGIC THERAPY FOR TYPE 1 DIABETES" rewritten to not only include afrezza but say afrezza should be frontline treatment for meal and pump bolusing. He can start with bullet 2 and should be able to do this in 6 months. care.diabetesjournals.org/content/41/Supplement_1/S73 After that he needs to have the PHARMACOLOGIC THERAPY FOR TYPE 2 DIABETES to include afrezza. This should be doable in 6 months. The third thing is he needs to have the "Recommendations" bullet three say afrezza should be used immediately for all PWDs over A1c 8.0 and all PWDs who do not reach 6.5 on Metformin in 6 months. Most of the rest of the bullets can be deleted as afrezza obsoletes their need. He should be able to this in 18 months but will need to bring the justification to ADA2019 as this is a huge battle, a $20B battle. If he can do these three things he will totally disrupt the diabetes industry and make MNKD a multi-$Billion company. I would argue that Afrezza should be added to bullet 2 on the basis of the Phase 3 trial (the trial found that RAA and Afrezza performed equally). Same argument for Type 2 treatment, there is an equivalence established. Six months seems a reasonable time to get it done. There is no way they make Afrezza a preferred treatment without a superiority trial. This is evidence based medicine and the classification matrix for evidence is clear on what is required (I feel we have had this evidence discussion before). That said 18 months is long enough to set up and run that trial so it's not an unreasonable timeframe. I suspect what the ADA will do is change all references to rapid acting insulin analogs or injections to simply rapid acting insulin. That would then cover both injected and inhaled insulin.
|
|
|
Post by peppy on Jun 27, 2018 10:41:39 GMT -5
Dr. Kendall needs to have the standard of care, the "PHARMACOLOGIC THERAPY FOR TYPE 1 DIABETES" rewritten to not only include afrezza but say afrezza should be frontline treatment for meal and pump bolusing. He can start with bullet 2 and should be able to do this in 6 months. care.diabetesjournals.org/content/41/Supplement_1/S73 After that he needs to have the PHARMACOLOGIC THERAPY FOR TYPE 2 DIABETES to include afrezza. This should be doable in 6 months. The third thing is he needs to have the "Recommendations" bullet three say afrezza should be used immediately for all PWDs over A1c 8.0 and all PWDs who do not reach 6.5 on Metformin in 6 months. Most of the rest of the bullets can be deleted as afrezza obsoletes their need. He should be able to this in 18 months but will need to bring the justification to ADA2019 as this is a huge battle, a $20B battle. If he can do these three things he will totally disrupt the diabetes industry and make MNKD a multi-$Billion company. I would argue that Afrezza should be added to bullet 2 on the basis of the Phase 3 trial (the trial found that RAA and Afrezza performed equally). Same argument for Type 2 treatment, there is an equivalence established. Six months seems a reasonable time to get it done. There is no way they make Afrezza a preferred treatment without a superiority trial. This is evidence based medicine and the classification matrix for evidence is clear on what is required (I feel we have had this evidence discussion before). That said 18 months is long enough to set up and run that trial so it's not an unreasonable timeframe. I suspect what the ADA will do is change all references to rapid acting insulin analogs or injections to simply rapid acting insulin. That would then cover both injected and inhaled insulin.That would be a good start.
|
|
|
ADA
Jun 27, 2018 10:50:04 GMT -5
peppy likes this
Post by agedhippie on Jun 27, 2018 10:50:04 GMT -5
I would argue that Afrezza should be added to bullet 2 on the basis of the Phase 3 trial (the trial found that RAA and Afrezza performed equally). Same argument for Type 2 treatment, there is an equivalence established. Six months seems a reasonable time to get it done. There is no way they make Afrezza a preferred treatment without a superiority trial. This is evidence based medicine and the classification matrix for evidence is clear on what is required (I feel we have had this evidence discussion before). That said 18 months is long enough to set up and run that trial so it's not an unreasonable timeframe. I suspect what the ADA will do is change all references to rapid acting insulin analogs or injections to simply rapid acting insulin. That would then cover both injected and inhaled insulin.That would be a good start. ... and a low hurdle so I think it gets done quite quickly. I would submit an edit with the trial data as the justification. I don't really see how it can get refused.
|
|
|
ADA
Jun 27, 2018 11:06:20 GMT -5
Post by peppy on Jun 27, 2018 11:06:20 GMT -5
the ada 2018 made a point of saying the committee may change anything at any time of the year, and put it out in a supplemental. start the clock.
I wish this stuff was easier to find. I do not want to read it again.
|
|
|
Post by sayhey24 on Jun 27, 2018 17:44:17 GMT -5
Dr. Kendall needs to have the standard of care, the "PHARMACOLOGIC THERAPY FOR TYPE 1 DIABETES" rewritten to not only include afrezza but say afrezza should be frontline treatment for meal and pump bolusing. He can start with bullet 2 and should be able to do this in 6 months. care.diabetesjournals.org/content/41/Supplement_1/S73 After that he needs to have the PHARMACOLOGIC THERAPY FOR TYPE 2 DIABETES to include afrezza. This should be doable in 6 months. The third thing is he needs to have the "Recommendations" bullet three say afrezza should be used immediately for all PWDs over A1c 8.0 and all PWDs who do not reach 6.5 on Metformin in 6 months. Most of the rest of the bullets can be deleted as afrezza obsoletes their need. He should be able to this in 18 months but will need to bring the justification to ADA2019 as this is a huge battle, a $20B battle. If he can do these three things he will totally disrupt the diabetes industry and make MNKD a multi-$Billion company. I would argue that Afrezza should be added to bullet 2 on the basis of the Phase 3 trial (the trial found that RAA and Afrezza performed equally). Same argument for Type 2 treatment, there is an equivalence established. Six months seems a reasonable time to get it done. There is no way they make Afrezza a preferred treatment without a superiority trial. This is evidence based medicine and the classification matrix for evidence is clear on what is required (I feel we have had this evidence discussion before). That said 18 months is long enough to set up and run that trial so it's not an unreasonable timeframe. I suspect what the ADA will do is change all references to rapid acting insulin analogs or injections to simply rapid acting insulin. That would then cover both injected and inhaled insulin. Aged - I sure hope you saw today's presentation.
Dr. Kendall seems to disagree with you on pretty much everything you said above. He called afrezza a "superior" insulin. He also said he already has more than enough studies to make things happen. Most interesting he said not making afrezza the standard of care would be both a moral issue and medical mistake. I was really surprised he pulled the moral card.
Dr. Kendall seems to have fire in the belly and is going to make things happen. Just as the standard of care for all MDI prior to RAA, whats that worth? I would say $1B. Assuming 200M outstanding shares, 50% margin and a P/E of 30, whats the share price at?
|
|
|
Post by mango on Jun 27, 2018 17:50:28 GMT -5
i'm not surprised at all, because it is medical negligence not to
|
|
|
Post by rockstarrick on Jun 27, 2018 17:52:56 GMT -5
I would argue that Afrezza should be added to bullet 2 on the basis of the Phase 3 trial (the trial found that RAA and Afrezza performed equally). Same argument for Type 2 treatment, there is an equivalence established. Six months seems a reasonable time to get it done. There is no way they make Afrezza a preferred treatment without a superiority trial. This is evidence based medicine and the classification matrix for evidence is clear on what is required (I feel we have had this evidence discussion before). That said 18 months is long enough to set up and run that trial so it's not an unreasonable timeframe. I suspect what the ADA will do is change all references to rapid acting insulin analogs or injections to simply rapid acting insulin. That would then cover both injected and inhaled insulin. Aged - I sure hope you saw today's presentation.
Dr. Kendall seems to disagree with you on pretty much everything you said above. He called afrezza a "superior" insulin. He also said he already has more than enough studies to make things happen. Most interesting he said not making afrezza the standard of care would be both a moral issue and medical mistake. I was really surprised he pulled the moral card. It was a great presentation !! I was surprised to hear that over 45 new drugs in the last decade, but still no increase in people @ goal. Until Afrezza and continuous glucose monitoring PWD were just treading water. It’ll be great to witness the change for the good over the next 10 years. Go Mannkind !! 😎
|
|